A study of MRI-guided diffuse fluorescence molecular tomography for monitoring PDT effects in pancreas cancer

Over the last several decades little progress has been made in the therapy and treatment monitoring of pancreas adenocarcinoma, a devastating and aggressive form of cancer that has a 5-year patient survival rate of 3%. Currently, investigations for the use of interstitial Verteporfin photodynamic therapy (PDT) are being undertaken in both orthotopic xenograft mouse models and in human clinical trials. In the mouse models, magnetic resonance (MR) imaging has been used as a measure of surrogate response to Verteporfin PDT; however, MR imaging alone lacks the molecular information required to assess the metabolic function and growth rates of the tumor immediately after treatment. We propose the implementation of MR-guided fluorescence tomography in conjunction with a fluorescently labeled (IR-Dye 800 CW, LI-COR) epidermal growth factor (EGF) as a molecular measure of surrogate response. To demonstrate the effectiveness of MR-guided diffuse fluorescence tomography for molecular imaging, we have used the AsPC-1 (+EGFR) human pancreatic adenocarcinoma in an orthotopic mouse model. EGF IRDye 800CW was injected 48 hours prior to imaging. MR image sequences were collected simultaneously with the fluorescence data using a MR-coupled diffuse optical tomography system. Image reconstruction was performed multiple times with varying abdominal organ segmentation in order to obtain a optimal tomographic image. It is shown that diffuse fluorescence tomography of the orthotopic pancreas model is feasible, with consideration of confounding fluorescence signals from the multiple organs and tissues surrounding the pancreas. MR-guided diffuse fluorescence tomography will be used to monitor EGF response after photodynamic therapy. Additionally, it provide the opportunity to individualize subsequent therapies based on response to PDT as well as to evaluate the success of combination therapies, such as PDT with chemotherapy, antibody therapy or even radiation.

[1]  R. Blumenthal,et al.  Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer , 2002, International journal of cancer.

[2]  Paul M. Ripley,et al.  Photodynamic therapy for cancer of the pancreas , 2002, Gut.

[3]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[4]  Tayyaba Hasan,et al.  Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. , 2010, International journal of radiation oncology, biology, physics.

[5]  M. Bettmann,et al.  Docetaxel/Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients With Pancreatic Adenocarcinoma , 2005, Annals of Surgical Oncology.

[6]  Stephen B. Tuttle,et al.  Magnetic resonance-coupled fluorescence tomography scanner for molecular imaging of tissue. , 2008, The Review of scientific instruments.

[7]  A. Zalatnai Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma. , 2007, Cancer treatment reviews.

[8]  Birgir Gudjonsson,et al.  Cancer of the pancreas: 50 years of surgery , 1987, Cancer.

[9]  Stephen G. Bown,et al.  Photodynamic Therapy Using Verteporfin Photosensitization in the Pancreas and Surrounding Tissues in the Syrian Golden Hamster , 2007, Pancreatology.

[10]  B. Pogue,et al.  Image-guided diffuse optical fluorescence tomography implemented with Laplacian-type regularization. , 2007, Optics express.

[11]  T. Yeatman,et al.  Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. , 2003, American journal of surgery.

[12]  A. Chatziioannou,et al.  Tomographic bioluminescence imaging by use of a combined optical-PET (OPET) system: a computer simulation feasibility study , 2005, Physics in medicine and biology.

[13]  Brian W. Pogue,et al.  Magnetic resonance image-guided photodynamic therapy of xenograft pancreas tumors with verteporfin , 2009, BiOS.